Kailera Therapeutics Inc. completed its initial public offering, selling 44,921,875 shares of common stock at a public offering price of $16.00 per share. The company reported gross proceeds from the offering of $718.8 million, a figure stated before the deduction of underwriting discounts and other expenses.
The sale reflected the full exercise of the underwriters' option to purchase an additional 5,859,375 shares. All shares in the transaction were offered directly by Kailera, and the offering did not include any selling shareholders.
Kailera's common stock began trading on the Nasdaq Global Select Market under the ticker symbol KLRA. The Waltham, Massachusetts-based company is focused on treatments for obesity and is in advanced clinical stages of development.
Several investment banks acted as joint book-running managers for the transaction: J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI. William Blair served as lead manager on the offering.
The Securities and Exchange Commission declared the company's registration statement on Form S-1 effective on April 16, 2026. The offering was conducted solely through a prospectus filed with the SEC, and the company announced the closing of the offering on April 20, 2026, according to a company press release.
Summary of transaction mechanics and timing:
- Shares sold: 44,921,875 common shares.
- Public offering price: $16.00 per share.
- Gross proceeds: $718.8 million, before underwriting discounts and other expenses.
- Underwriters' full option exercised: 5,859,375 additional shares.
- Market listing: Nasdaq Global Select Market, ticker KLRA.
- SEC Form S-1 declared effective: April 16, 2026; offering closing announced: April 20, 2026.
This transaction adds a newly listed entrant to the public biotech market, with the company positioning itself in obesity care and reporting that its development programs are at advanced clinical stages. The offering was structured and managed by a syndicate of major investment banks, with William Blair as lead manager and a group of joint book-running managers supporting the sale.